PUT - SPRINTER OPEN END - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 16:03:58 30/05/2024 BST | ||
| 2.59 EUR | -1.89% |
|
| Current month | -2.94% | ||
| 1 month | -10.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 30/05/24 | 2.59 | -1.89% |
| 29/05/24 | 2.64 | +1.15% |
| 28/05/24 | 2.61 | +6.10% |
| 27/05/24 | 2.46 | +7.42% |
| 24/05/24 | 2.29 | +2.23% |
Real-time Boerse Frankfurt Warrants
Last update May 30, 2024 at 04:03 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XA1 |
| ISIN | DE000VD1XA13 |
| Date issued | 08/03/2024 |
| Strike | 1,110 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.72 € |
|---|---|
| Lowest since issue | 2.22 € |
| Spread | 0.07 € |
| Spread % | 2.63% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
911.5
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.63%
- Stock Market
- Certificates
- Certificat
